EDHARRINGTON's journey to regrow his hair using finasteride, topical minoxidil, and micro-needling treatments over 4 years, with others commenting their support and admiration for his results.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
A user shared progress pictures showing significant hair regrowth from using 1mg finasteride, Minoxidil, vitamins, and dermarolling over 4 months. The user reported no side effects and takes a generic multivitamin and biotin.
A 36-year-old started using finasteride (0.3-0.5mg daily), 5% minoxidil foam, and weekly dermarolling/dermapen treatments to address hair loss. They also began taking supplements for low ferritin and vitamin D, hoping to improve hair thickness and cover a bald spot.
A 20-year-old male shared his 4-month hair regrowth results using finasteride, minoxidil, nizoral, and dermarolling. Commenters noted improved hair density and the potential for further progress.
A 20-year-old has seen positive results for hair loss after 4 months using 1 mg finasteride daily, minoxidil twice daily, and weekly dermastamping with a 1.5 mm needle. They also used ketoconazole shampoo initially and recommend starting treatment early.
User shared 3-month progress using big 4 hair loss treatments: finasteride, ketoconazole shampoo, minoxidil, and microneedling. Others congratulated progress and discussed vitamin D and biotin's role in hair regrowth.
User shares progress after 4 months of using finasteride and dermarolling, with occasional use of coconut and rosemary oil. They aim to stop hair loss and hope for increased top density.
A user shared their 4-month progress using 1mg finasteride and minoxidil foam once a day for hair loss. Another user complimented the results and asked about their age.
A 36-year-old considering a fourth hair transplant is advised to either shave his head or use a hair system due to poor results from previous transplants and late medication use. He plans to consult top surgeons and adjust his current treatments, including finasteride and minoxidil.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
The conversation is about someone's 4-month hair regrowth progress using 0.5mg dutasteride and topical minoxidil. Another person is inspired and is using 5mg finasteride and 5% minoxidil topically twice daily, hoping for similar results.
The user experienced significant hair regrowth and improved hair density after four months using finasteride, minoxidil, and microneedling, avoiding the need for a hair transplant. They plan to continue their current routine due to positive results and are not considering switching to dutasteride.
The user shared progress pictures showing hair improvement over four months using 1 mg finasteride and 5 mg minoxidil daily. They reported no significant side effects and plan to reduce the minoxidil dose once satisfied with the results.
The user experienced hair regrowth using finasteride, minoxidil, dermarolling, and a castor oil and peppermint mix after initially having a significant hair loss. They reported no lasting side effects from finasteride and believe dermarolling contributed to their hairline growth.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
A user shared their 4-month progress using a topical solution with 5% minoxidil and 0.1% finasteride, applied twice daily. They reported good results despite occasional missed applications.
The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.
The conclusion of the conversation is that the user experienced noticeable regrowth of hair after using dutasteride as a single treatment for about 1.5 years. No before photos were available.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.
The user shared their positive 5-month results using finasteride, minoxidil, derma rolling, and supplements like biotin, zinc, iron, and vitamin C. They provided before and after photos and mentioned applying minoxidil even when derma rolling.
A 19-year-old reports positive hair regrowth using oral minoxidil and finasteride, with no side effects. The conversation includes advice on consulting a dermatologist and exploring alternative treatments.
A user reported significant hair regrowth after 4 months using finasteride and minoxidil, with no major side effects. They are considering oral minoxidil and use microneedling and ketoconazole shampoo.
People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.